Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
3 Months Ended 6 Months Ended 181 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Revenues:          
Grant revenue          $ 200,400 $ 12,963,100
Collaboration revenue             2,283,600
Other             1,123,500
Total revenues          200,400 16,370,200
Operating expenses:          
Research and development 669,300 1,106,300 1,364,800 1,972,600 30,920,500
Acquired in-process research and development             7,523,200
General and administrative 545,900 575,900 1,150,500 1,631,200 31,831,600
Total operating expenses 1,215,200 1,682,200 2,515,300 3,603,800 70,275,300
Loss from operations (1,215,200) (1,682,200) (2,515,300) (3,403,400) (53,905,100)
Other expenses, net:          
Interest expense, net (323,200) (273,500) (639,600) (376,300) (11,001,800)
Change in warrant put and note extension option and warrant liabilities 78,600    1,883,500    666,200
Loss on early extinguishment of debt             (4,761,300)
Other income             81,900
Loss before income taxes (1,459,800) (1,955,700) (1,271,400) (3,779,700) (68,920,100)
Income taxes       (2,700) (1,900) (23,200)
Net loss (1,459,800) (1,955,700) (1,274,100) (3,781,600) (68,943,300)
Basic net income (loss) per share $ (0.07) $ (0.12) $ (0.06) $ (0.22)  
Weighted average shares used in computing basic and diluted net loss per share 21,630,587 17,094,833 21,225,315 16,969,433  
Comprehensive loss $ (1,459,800) $ (1,955,700) $ (1,274,100) $ (3,781,600) $ (68,943,300)